Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity.

This article discusses a study on the drug dupilumab and its effectiveness in treating atopic dermatitis (AD) in obese patients. The study found that dupilumab was effective in treating AD in obese patients, although the response rate was slightly lower compared to non-obese patients. The study also observed weight changes in both groups, with some patients experiencing weight gain and others experiencing weight loss. The authors recommend weight monitoring during treatment and suggest that optimized dosages may be considered for obese patients. The study was supported by the FRADEN/F-CRIN network and the authors disclose potential conflicts of interest. This document is a letter to the editor written by dermatologists and researchers from various hospitals and institutions in France. The letter discusses the potential factors influencing dupilumab response, the impact of body mass index on treatment outcomes, and weight gain in patients receiving dupilumab. The study was approved by an ethics committee and the data supporting the findings are available upon request. [Extracted from the article]